Is There a Place for Medicinal Cannabis in Treating Patients with Sleep Disorders? What We Know so Far

被引:10
|
作者
Maddison, Kathleen J. [1 ,2 ]
Kosky, Christopher [1 ]
Walsh, Jennifer H. [1 ,2 ]
机构
[1] Sir Charles Gairdner Hosp, West Australian Sleep Disorders Res Inst, Dept Pulm Physiol & Sleep Med, Perth, WA, Australia
[2] Univ Western Australia, Ctr Sleep Sci, Perth, WA, Australia
来源
NATURE AND SCIENCE OF SLEEP | 2022年 / 14卷
关键词
cannabinoid; insomnia; obstructive sleep apnea; restless legs syndrome; REM behavior disorder; nightmare disorder; BEHAVIOR DISORDER; REM-SLEEP; ADMINISTERED DELTA-9-TETRAHYDROCANNABINOL; NIGHTMARE DISORDER; AMERICAN ACADEMY; PRACTICE GUIDE; DOUBLE-BLIND; CHRONIC PAIN; MARIJUANA; EFFICACY;
D O I
10.2147/NSS.S340949
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The legalization of cannabis for medicinal, and in some countries, recreational, purposes in addition to growth in the cannabis industry has meant that cannabis use and interest in the area has increased rapidly over the past 20 years. Treatment of poor sleep and sleep disorders are two of the most common reasons for the current use of medicinal cannabis. However, evidence for the role of medical cannabis in the treatment of sleep disorders has not been clearly established, thus making it challenging for clinicians to make evidence-based decisions regarding efficacy and safety. This narrative review summarizes the highest quality clinical evidence currently available in relation to the use of medicinal cannabis for the treatment of sleep disorders including insomnia, obstructive sleep apnea, restless legs syndrome, rapid eye movement sleep behavior disorder, nightmare disorder and narcolepsy. A summary of the effect of cannabis on sleep quality and architecture is also presented. Currently, there is insufficient evidence to support the routine use of medicinal cannabis as an effective and safe treatment option for any sleep disorder. Nevertheless, emerging evidence is promising and warrants further investigation using standardized cannabinoid products and validated quantitative measurement techniques.
引用
收藏
页码:957 / 968
页数:12
相关论文
共 50 条
  • [21] Octreotide and postoperative pancreatic fistula after pancreaticoduodenectomy: What we know so far? A narrative review
    Tilak, Mandar
    Tewari, Mallika
    Shukla, H. S.
    INDIAN JOURNAL OF CANCER, 2023, 60 (02) : 152 - 159
  • [22] Postoperative Spinal Implant Infections (PSII)-A Systematic Review: What Do We Know So Far and What is Critical About It?
    Karczewski, Daniel
    Schnake, Klaus J.
    Osterhoff, Georg
    Spiegl, Ulrich
    Scheyerer, Max J.
    Ullrich, Bernhard
    Pumberger, Matthias
    GLOBAL SPINE JOURNAL, 2022, 12 (06) : 1231 - 1246
  • [23] Sleep Disorders in Women: What Should a Gynecologist Know?
    Aksan, Alperen
    Dilbaz, Berna
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2024, 84 (11) : 1043 - 1049
  • [24] The role of sleep in PCOS: what we know and what to consider in the future
    Teo, Peiseah
    Henry, Belinda A.
    Moran, Lisa J.
    Cowan, Stephanie
    Bennett, Christie
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2022, 17 (04) : 305 - 318
  • [25] Monoclonal Antibodies Targeting CGRP: From Clinical Studies to Real-World Evidence-What Do We Know So Far?
    Mavridis, Theodoros
    Deligianni, Christina, I
    Karagiorgis, Georgios
    Daponte, Ariadne
    Breza, Marianthi
    Mitsikostas, Dimos D.
    PHARMACEUTICALS, 2021, 14 (07)
  • [26] Immune activities of polysaccharides isolated from Lycium barbarum L. What do we know so far?
    Xiao, Zhiyong
    Deng, Qi
    Zhou, Wenxia
    Zhang, Yongxiang
    PHARMACOLOGY & THERAPEUTICS, 2022, 229
  • [27] Erythropoietin Administration for Anemia Due to Chronic Kidney Disease Subcutaneous OR Intravenous, What Do We Know So Far?
    Shahab, Muhammad Hasan
    Khan, Shahzeen Saifullah
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (09)
  • [28] Alternative algorithms and devices in sleep apnoea diagnosis: what we know and what we expect
    Penzel, Thomas
    Fietze, Ingo
    Glos, Martin
    CURRENT OPINION IN PULMONARY MEDICINE, 2020, 26 (06) : 650 - 656
  • [29] Treating Postpartum Depression: What Do We Know about Brexanolone?
    Ali, Muneeza
    Aamir, Alifiya
    Diwan, Mufaddal Najmuddin
    Awan, Hashir Ali
    Ullah, Irfan
    Irfan, Muhammad
    De Berardis, Domenico
    DISEASES, 2021, 9 (03)
  • [30] Central serous chorioretinopathy: what we have learnt so far
    Wong, Kah Hie
    Lau, Kin Pong
    Chhablani, Jay
    Tao, Yong
    Li, Qing
    Wong, Ian Y.
    ACTA OPHTHALMOLOGICA, 2016, 94 (04) : 321 - 325